Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

by B2i | Aug 10, 2022 | Press Releases

Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from proprietary C1-cell protein production platform and demonstrate...

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

by B2i | Jul 27, 2022 | Press Releases

JUPITER, Fla., July 27, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...

Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting

by B2i | Jul 5, 2022 | Press Releases

JUPITER, Fla., July 05, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary and patented microbial technologies...

Dyadic to Participate in Three Upcoming Industry Events

by B2i | Jun 9, 2022 | Press Releases

JUPITER, Fla., June 09, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1 protein production platform to...

Dyadic to Present at 2022 Jefferies Healthcare Conference

by B2i | Jun 2, 2022 | Press Releases

JUPITER, Fla., June 02, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform...